These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1294 related articles for article (PubMed ID: 33150470)

  • 1. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
    Cattaneo D; Pasina L; Maggioni AP; Giacomelli A; Oreni L; Covizzi A; Bradanini L; Schiuma M; Antinori S; Ridolfo A; Gervasoni C
    Drugs Aging; 2020 Dec; 37(12):925-933. PubMed ID: 33150470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
    Cantudo-Cuenca MD; Gutiérrez-Pizarraya A; Pinilla-Fernández A; Contreras-Macías E; Fernández-Fuertes M; Lao-Domínguez FA; Rincón P; Pineda JA; Macías J; Morillo-Verdugo R
    Sci Rep; 2021 Jun; 11(1):12414. PubMed ID: 34127740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
    Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
    Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients.
    Cattaneo D; Pasina L; Maggioni AP; Oreni L; Conti F; Pezzati L; Casalini G; Bonazzetti C; Morena V; Ridolfo A; Antinori S; Gervasoni C
    Drugs Aging; 2021 Apr; 38(4):341-346. PubMed ID: 33646509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.
    Crescioli G; Brilli V; Lanzi C; Burgalassi A; Ieri A; Bonaiuti R; Romano E; Innocenti R; Mannaioni G; Vannacci A; Lombardi N
    Intern Emerg Med; 2021 Apr; 16(3):697-710. PubMed ID: 33355896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
    Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
    J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
    Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
    Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
    Schneider J; Jaenigen B; Wagner D; Rieg S; Hornuss D; Biever PM; Kern WV; Walz G
    PLoS One; 2021; 16(5):e0249760. PubMed ID: 33974624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
    Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
    Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
    Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
    Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
    Alabdalaali MM; Hadi AM
    Arch Razi Inst; 2023 Jun; 78(3):935-941. PubMed ID: 38028857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
    Boari GEM; Chiarini G; Bonetti S; Malerba P; Bianco G; Faustini C; Braglia-Orlandini F; Turini D; Guarinoni V; Saottini M; Viola S; Ferrari-Toninelli G; Pasini G; Mascadri C; Bonzi B; Desenzani P; Tusi C; Zanotti E; Nardin M; Rizzoni D
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33201172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
    Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatments for SARS-CoV-2 infection: A retrospective study of drug-drug interactions and safety].
    Dubois A; Féral A; Pain JB; Michot J; Fansi Ndengoue D; Benomar A; Clou E; Debrix I
    Ann Pharm Fr; 2022 Jul; 80(4):531-542. PubMed ID: 34748737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of drugs against COVID-19.
    Tan J; Yuan Y; Xu C; Song C; Liu D; Ma D; Gao Q
    Virus Res; 2021 Mar; 294():198262. PubMed ID: 33333102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.